Stocks · News reference
Dow Surges Over 200 Points; Ollie's Bargain Outlet Shares Gain After Q2 Earnings
U.S. stocks edged higher, led by the Dow and materials. Ollie’s beat EPS estimates; biotech and AI shares surged, while Tscan plunged 26%.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Alpha Modus shares are trading higher after the company announced that its subsidiary, Alpha Modus Corp., entered into an agreement with Autry Greer & Sons to test and evaluate its proprietary ARIA AI platform within Greer’s grocery retail operations.
Alpha Modus Holdings Inks Agreement With Autry Greer & Sons To Test, Evaluate Adaptive Retail Intelligence Architecture AI Platform
Alpha Modus Holdings, Inc. (NASDAQ: AMOD) ("Alpha Modus" or the "Company"), an artificial intelligence technology company focused on transforming physical retail through advanced data intelligence, today
Shares of software companies are trading lower as elevated oil prices and stronger-than-expected inflation data fuel expectations of more Fed tightening at a quicker pace. Costlier borrowing may weaken sentiment for the sector's strong H2 2026 rally.
bioAffinity Technologies To Present New Data On Sputum-Based Tests In Development To Characterize Lung Inflammation And Detect Multiple Protein Biomarkers Of Lung Inflammation At CHEST 2026
Findings report on ability to measure cellular and soluble inflammatory protein biomarkers in sputum, including biologic drug targetsCompany advances research and development in diagnostic tests for major lung diseases
BIAF stock has given up its prior gain. bioAffinity Technologies shares were trading higher after the company announced that the Japan Patent Office issued a Notice of Allowance indicating its intention to grant a patent for the method of predicting the likelihood of lung cancer powered by the CyPath Lung test for early-stage lung cancer.